My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

United Therapeutics Corporation - Common Stock (NQ:UTHR)

473.42 -7.10 (-1.48%)

Official Closing Price Updated: 4:15 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1

April 30, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of...

Via StockStory

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

April 29, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

Via StockStory

Topics Government World Trade

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗

April 25, 2025

Via Benzinga

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday ↗

April 25, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

How Is The Market Feeling About United Therapeutics? ↗

January 01, 2025

Via Benzinga

$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today ↗

December 11, 2024

Via Benzinga

Demystifying United Therapeutics: Insights From 4 Analyst Reviews ↗

April 25, 2025

Via Benzinga

How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles? ↗

April 11, 2025

Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fits the characteristics of a...

Via Chartmill

2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question

April 11, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

How Is The Market Feeling About United Therapeutics? ↗

November 26, 2024

Via Benzinga

Earnings Outlook For United Therapeutics ↗

October 29, 2024

Via Benzinga

Decoding 7 Analyst Evaluations For United Therapeutics ↗

October 21, 2024

Via Benzinga

Why Quality Investors May Find UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Attractive. ↗

April 04, 2025

A fundamental analysis of (NASDAQ:UTHR): Is UNITED THERAPEUTICS CORP (NASDAQ:UTHR) a Strong Candidate for Quality Investing?

Via Chartmill

3 Reasons Investors Watch United Therapeutics (UTHR)

March 28, 2025

Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop. This was partly due to its softer quarterly results...

Via StockStory

Topics Stocks

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

March 20, 2025

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

March 18, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

The Analyst Landscape: 7 Takes On United Therapeutics ↗

October 21, 2024

Via Benzinga

$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today ↗

October 15, 2024

Via Benzinga

Evaluating UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s legendary strategy ↗

March 17, 2025

With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put UNITED THERAPEUTICS CORP (NASDAQ:UTHR) to the test against his...

Via Chartmill

2 Value Stocks on Our Watchlist and 1 to Ignore

March 12, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Why United Therapeutics (UTHR) Stock Is Down Today

February 26, 2025

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations,...

Via StockStory

United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations

February 26, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was...

Via StockStory

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

February 25, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Via StockStory

United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?

February 14, 2025

United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%.

Via StockStory

Topics Stocks

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗

October 15, 2024

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

Via Investor's Business Daily

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗

October 14, 2024

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.